focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Wow .. even GSK is blue today, incredible, will it stay blue until until noon?
I don't get it ,this should be above 18 pounds ,,as pipelines are get results
Remember the stock market is fickle. What we do know is there have been Getting ahead of Infectious Disease, HIV and Respiratory Disease with GSK management presentations with Oncology to come next year. Peak Year Sales for late stage assets have been stated as follows :
RSV. £3bn
Men ABCWY. £2bn
Gepotidacin, tebi & Brexafemme. £2bn
HBVASO. £2bn
Pneumococcal £4bn
Cabenuva/Prep. £2bn
Depemokimab. £3bn
Camlipixant. £2.5bn
Nucala COPD. £1bn
Assuming no change from two years ago for Jemperli and half the sales for Zejula and nothing for Blenrep (v conservative given Dream 7 last week)
Jemperli £2bn
Zejula. £1bn
Assume Ojjaara £1.5bn
Total PYS of £21-26bn across a number of assets. We also know the SP will go nowhere until Zantac litigation is resolved. If management can resolve Zantac next year and start to deliver on the pipeline the future is brighter than the current SP would suggest.
SamMason55 - its just a case of how patient you feel you can be. Remember this is the stock market so the grass is not always greener elsewhere! If you really are determined to get out, then get out without further delay. If your p/f is overweight GSK, you could consider encashing some (but check the ex-divi date first). I've been doing this for 60 years and heaven knows how much I am down but I think I'm getting the hang of it now -a bit!!
Why does all this great news make no difference to the SP? We should be more than £20 to align to peers.
https://www.londonstockexchange.com/news-article/GSK/gsk-announces-positive-dreamm-7-headline-results/16224766
All IMHO DYOR
Happy
Report in Sunday Times this weekend inferred Zantac claims in USA
have depressed SP
I cannot believe GSK is sitting at this miserable price of a little over £13.80. I fully expected the share to rise towards or above £16 after the results readout (which were fantastic by the way). Yet since then they have dropped approx 7%. Before the quarterly results the share was still on an upward trend yet now they are below YTD and only half a percent higher than a year ago.
Settled court cases, quarter on quarter excellent results, great pipeline, blockbuster launches and increased forecast seem to make no difference.
I’m not sure if it is poor leadership or market bias against GSK but something is not adding up.
After 15 years in this share, the lowered dividend without any likelihood of this increasing means I will probably move on if we get above £15.
FX USD/GBP
Big up day for most decent shares today. Still wildly undervalued!
It's started .......let's hope it continues.....
Https://www.londonstockexchange.com/news-article/GSK/gsk-receives-positive-chmp-opinion-for-momelotinib/16206079
At what point does our SP respond?
All IMHO DYOR
Happy
...be rather helpful here. Don't really have lots of gaining shares in the p/f to sell in order to buy more GSK but if this SP continues to drift, might have to do just that. Incidentally, inserting a $B3 loss fund for Zantac payments seems harsh on GSK but then everyone seems to have it in for them these days!
It is Pfizer who are making the maternal RSV vaccine, not GSK.
https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-abrysvotm-pfizers-vaccine-prevention-0
I am getting a video picture in picture about one tenth of screen every time I open a share on my saved shares list.
Its not an add, its actually vids about companies. anyone know how to stop this please. W10. Brave browser. Apart from this add free.
I was listening to the latest TWiV [This Week in Virology]... They mentioned that GSK have got 2/3s of the market in the US, that the CDC is now recommending the vaccines to over 60s & that they want pregnant women in their last trimester to be vaccinated to pass on the antibodies to newborns. Sales of the RSV vaccine might surpass market expectations.
https://www.youtube.com/watch?v=hKfU4g1MKZM
Well documented to be replaced by far better and less regular treatments. The only concern still hanging over GSK is the Zantac lawsuit
HIV patent expires soon for starters
Solomon - Arexvy was a big feature in yesterday's post result webcast and it is what virtually all the analysts wanted to talk about. It was only launched in Q3 and achieved sales of £709m "benefitting from strong demand and initial channel inventory build. It has approval in US, EU, Canada and Japan but it is far too early to say if it is going to be a "winner" or not. They need more efficacy studies; they undertook one on 50 - 59 year olds which showed "positive data" and are working on others. They did say they were beating Pfizer on RSV products but it really is too soon to judge but you are correct in saying there is some inventory build and there will be this time next year because of the seasonal bias in it's use.
The share price has been awful since yesterday's profit upgrade but looking at the trades it doesn't look like chunky institutional business. Who knows how the Zantac litigation will turn out - here is what the company has to say about it https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation/ I'm sticking with my shares and a "buy" status but like everyone I get some wrong!
Ok. It sounds like the company are being more guarded about Arexvy growth and just tempering expectations for ‘24. It doesn’t take much to know this when everyone is so utterly bored of it. Hard to believe I once sold these shares at £20 in the late 90’s. Wish I’d just left them alone ever since. I see a few comments here about a potential bid for them. It feels unlikely given their perceived strategic importance to the politicians, but I know institutions would bite the hand off anyone bidding much above say £18
Just came on here to try and find out what’s happened. It’s weird isn’t it? There must be some big downgrade around. I’ll dig around and come back.
I guess that its down to the usual culprits. Institutional selling, disappointment in not meeting the "whisper" number, and company debt. Leaving out the ongoing Zantec litigation.